# A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Study · id `cardio:ct-nct03422328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03422328](<https://clinicaltrials.gov/study/NCT03422328>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03422328

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT03422328. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2023-12-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT03422328, source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)
- Started: 2018-04-05 (actual) (ClinicalTrials.gov record NCT03422328, source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)
- Primary completion: 2023-12-27 (actual) (ClinicalTrials.gov record NCT03422328, source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)
- Completion: 2023-12-27 (actual) (ClinicalTrials.gov record NCT03422328, source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)
- Countries: Belarus; Belgium; France; Poland; Russia; Türkiye; Ukraine (ClinicalTrials.gov record NCT03422328, source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03422328-2025-04-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
- Acronym: UMBRELLA
- Condition: Pulmonary Arterial Hypertension
- Condition: Chronic Thromboembolic Pulmonary Hypertension
- Intervention (Drug): macitentan
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: 68eed971df7d9285113e044763e37270fea4d7f6b9986c421b93b1ad3b607755
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
